Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Cloxacillin Cefazolin Infective Endocarditis
DOI: 10.1016/j.ijid.2023.10.019 Publication Date: 2023-11-04T06:42:27Z
AUTHORS (414)
ABSTRACT
Objective: The aim of this study was to assess the real use cefazolin for methicillin-susceptible S. aureus (MSSA) infective endocarditis (IE) in Spanish National Endocarditis Database (GAMES) and compare it with antistaphylococcal penicillins (ASP).Methods: Prospective cohort retrospective analysis a MSSA IE treated cloxacillin and/or cefazolin. Outcomes assessed were: relapse; intra-hospital, overall endocarditis-related mortality; adverse events. Risk renal toxicity each treatment evaluated separately.Results: We included 631 episodes caused by Antibiotic cloxacillin, or both 537(85%), 57(9%) 37(6%) respectively. Patients had significantly higher rates comorbidities (median Charlson Index 7, p<0.01) previous failure (57.9%, p<0.01). presented septic shock (25%, p=0.033) new-onset worsening (47.3%, p=0.024) in-hospital mortality (38.5%, p=0.017). One-year related rate relapses similar between groups. None treatments were identified as risk protective factors.Conclusion: Our results suggest that is valuable option IE, without differences one-year compared might be considered equally effective.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (4)